Oncodesign Precision Medicine Société anonyme announced that it has received an equity round of funding for gross proceeds of ?22 million on January 23, 2024. The transaction included participation from new investor NOV Santé Actions Non Cotées, a fund managed by Eurazeo SE; management and ERES IV SLP.